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behind targeted approaches that have been and are undergoing exploration in mesothelioma and 
summarizes available clinical results and ongoing efforts to improve the systemic therapy of 
mesothelioma." 
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Abstract 
Malignant mesothelioma is an incurable disease associated with asbestos exposure 
arising in the pleural cavity and less frequently in the peritoneal cavity. Platinum-based 
combination chemotherapy with pemetrexed is the established standard of care. 
Multimodality approaches including surgery and radiotherapy are being investigated. 
Increasing knowledge about the molecular characteristics of mesothelioma had led to 
the identification of novel potential targets for systemic therapy. Current evidence 
suggests pathways activated in response to merlin deficiency, including Pi3K/mTOR and 
the focal adhesion kinase, as well as immunotherapeutic approaches to be most 
promising. This review elaborates on the rationale behind targeted approaches that 
have been and are undergoing exploration in mesothelioma and summarizes available 
clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.  
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Introduction 
Mesothelioma is a fatal disease predominantly arising in the pleural cavity and less so in 
the peritoneal cavity. The association of mesothelioma with asbestos exposure is well 
established. The time from exposure to the diagnosis is on the average greater than 40 
years, explaining why the disease incidence is still raising in many countries despite 
working bans on the use of asbestos in the early 1990s. Platinum-based chemotherapy, 
mostly combined with the folate antagonist pemetrexed, is the established standard of 
care [1]. In earlier stages of pleural mesothelioma multimodality therapy including 
extrapleural pneumonectomy or more recently extended pleurectomy/decortication, with 
or without radiotherapy, are being investigated in selected patients [2]. There is currently 
no defined standard for second line therapy.  The rationale behind investigating novel 
targeted approaches, available results and ongoing efforts are summarized in this 
review. 
 
 
Exploring molecular alterations   
 
Data mining of version 71 of the catalogue of somatic mutations in cancer (COSMIC, 
http://www.sanger.ac.uk/cosmic) reveals that the genes that are most frequently 
mutated in malignant pleural mesothelioma are cyclin-dependent kinase inhibitor 2A 
(CDKN2A), neurofibromatosis type 2 (NF2) and BRCA-associated protein 1.   
 
Targeting the cell cycle:  
Mesothelioma lack expression of both CDKN2A encoded proteins p16 and ARF due to 
gene deletion  or methylation (reviewed in [3]). Deletion in CDKN2A leads to loss of 
control of cyclin D-dependent kinases (CDK). Although CDK4/6 specific inhibitors are 
under investigation in clinical trials, animal models with CDKN2A deficiency showed that 
loss of CDKN2A function is not necessarily associated with CDK4/6 addiction [4]. 
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Although only a minor fraction of mesothelioma presents with p53 mutations [5], this 
lead to the hypothesis that this tumor might be dependent on G2 checkpoint and 
therefore vulnerable to a G2 checkpoint inhibition when combined with chemotherapy. In 
line with this hypothesis, the calmodulin-binding peptide (CBP501) was clinically tested 
in combination with cisplatin and pemetrexed in order to increase the sensitivity of 
mesothelioma cells to chemotherapy [6]. In patients receiving CBP501 with 
chemotherapy PFS of more than 4 months was achieved compared to 39% receiving 
chemotherapy alone (Table 1) [7] 
 
Targeting NF2/Hippo deficiency:  
The NF2/Hippo signalling pathway has been shown to be disrupted in most 
mesothelioma [5] [8] characterized by mutation or inactivation of the NF2 gene (reviewed  
in [3]). Experimental animal models indicate that this event, together with a deficiency in 
cyclin-dependent kinase activator inhibitor (CDKN2A), is essential for mesothelioma 
development. Therefore, targeting molecules involved in the NF2/Hippo pathway is of 
major interest (Figure 1) for the treatment of mesothelioma. NF2 is an upstream 
regulator of the so-called Hippo signalling cascade, [9] which controls the transcriptional 
co-activator Yes-associated protein (YAP)). The dysfunction of Hippo pathway, which 
leads to increased YAP activity [10], induces oncogenic transformation by the activation 
of transcription factors including transcription enhancers activation domain (TEAD) 
family members [11]. Upon binding TEADs, YAP/TAZ up-regulates the expression of 
several growth promoting factors. YAP is constitutively active in more than 70% of 
primary mesotheliomas [8], [12]. Hedgehog signalling has a role in maintaining YAP 
protein stability in progenitor cells [13] and is activated in mesothelioma, consistent with 
the re-activation of a signalling known to be essential during embryonic mesothelial 
development [14].  Treatment of mesothelioma xenografts with the hedgehog antagonist 
HhAntag led to a decrease of the tumour volume accompanied by a decrease in Ki-67 
labelling index.  
 
Another possible approach is the direct inhibition of YAP activity. Three compounds 
related to porphyrin that could inhibit the transcriptional activity of YAP in vitro were 
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identified by screening of a Johns Hopkins Drug Library [15]. One of these, verteporfin, 
in clinical use as a photosensitizer in photocoagulation therapy for macular 
degeneration, was moderately effective at blocking mouse Yap1-overexpression- or loss 
of Nf2-driven hepatic tumorigenesis. These data suggest further investigation of these 
compounds as anticancer therapies.  
NF2 suppresses tumorigenesis by migrating into the nucleus where it inhibits the E3 
ubiquitin ligase CRL4 and through that controls a subset of Hippo pathway target genes 
[16], therefore CRL inhibitors such as MLN4924 should be investigated in 
mesothelioma.   
 
Interestingly, expression of constitutively active YAP causes widespread miRNA 
suppression [17]. Thus, the Hippo pathway may be responsible for the widespread 
miRNA repression observed in cancer, including mesothelioma. To overcome the 
difficulties of directly delivering miRNA mimics, minicells composed of achromosomal 
bacterial cells and targeted by bispecific antibodies, have been developed. These have 
been used to restore miR16 and induce growth arrest in mesothelioma xenografts [18]. 
Minicells can be given safely to patients with advanced cancer [19] and a clinical trial 
has started in mesothelioma (ACTRN12614001248651). 
 
Targeting NF2 associated cytoskeletal alterations: 
In a systematical screen for tumor suppressors whose functional inactivation would 
result in microtubular instability, NF2 was identified as a microtubule stabilizer [20], 
demonstrating that the microtubular network might be significantly affected in 
mesothelioma. Based on this and in vitro studies, epothilone B would be a candidate for 
clinical evaluation [21] . 
 
NF2 alterations result also in activation of the focal adhesion kinase (FAK) and merlin 
deficiency predicts for sensitivity to FAK inhibitors [22, 23]. The underlying mechanism is 
that survival and proliferation signals seem mediated through extracellular matrix-
integrin signals promoting FAK activation in mesothelioma cells with inactivating NF2 
mutations [23]. There is a phase I and two phase II trials ongoing testing the FAK 
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inhibitors GSK2256098 and defactinib (VS-6063) in mesothelioma (Table 1). 
Determination of the NF2 status in these trials will allow exploring whether the clinical 
outcome is indeed associated with alteration of NF2.  
 
Targeting PI3K/mTOR 
PI3K/mTOR signalling is activated in mesothelioma [24]. For the time being the reason 
for this has not been elucidated, as neither PI3K nor receptor tyrosine kinase 
mutations/amplifications have been found in two recent high-throughput studies [5] [25]. 
NF2-null cells were shown sensitive to growth inhibitory effects of rapamycin [26] via 
mechanisms involving PI3K signalling-independent mammalian target of rapamycin 
complex (mTORC1) activation. However, preliminary results of a phase II trial [27] of the 
mTOR inhibitor, everolimus, did not show to be active in unselected MPM patients 
(Table 1). In addition, a peritoneal mesothelioma model was recently generated by 
deficiency in p53 and the tuberous sclerosis gene, a negative regulator of mTORC [28]. 
GDC-0980 is a small molecule inhibitor of class I PI3K and mTOR (mTORC1 and 
mTORC2) [29] has been tested in phase I studies (Table 1) and the preliminary result of 
the phase I extension cohort showed two objective responses among 26 patients with 
mesothelioma [30]. Another dual PI3K/mTOR inhibitor, LY3023414 is tested in a phase I 
trial (Table 1). 
 
 
Synthetic lethal approaches  
A large proportion of mesothelioma [31] show reduced expression of arginosuccinate 
synthetase-1, the rate-limiting enzyme for arginine biosynthesis, rendering cells 
auxotrophic for arginine and consequently susceptible to the arginine degrading enzyme 
arginine deiminase (Adi-PEG20). Preliminary results of a randomized phase II study 
(Table 1) showed a significant PFS improvement delivering ADI-PEG20 versus best 
supportive care [32]. Almost all epithelioid and about 50% of sarcomatoid mesothelioma 
express calretinin [33] which is widely used as a robust diagnostic mesothelioma 
marker. Since its silencing inhibits mesothelioma cell survival in vitro, this may offer 
another opportunity for a therapeutic intervention [34] . 
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Tyrosine Kinase Inhibitors (TKIs):  
 
Deregulated expression of growth factors or proteins involved in downstream signalling 
pathways has been shown to play an important role in malignant transformation of 
mesothelial cells. Molecular studies in malignant pleural mesothelioma have confirmed 
that growth factors such as vascular endothelial growth factor (VEGF), platelet-derived 
growth factor receptor beta (PDGFR) and the epidermal growth factor receptor family 
are frequently activated. Several clinical trials have tried to exploit these specific 
characteristics using tyrosine kinase inhibitors.  
 
Multitarged TKIs  
Overexpression of platelet-derived growth factor (PDGF) has been observed and found 
to be associated with a poor prognosis [35]. While normal mesothelial cells express 
predominantly the PDGFRα subunit and less PDGFRβ, mesothelioma was shown to 
overexpress PDGFRβ [36]. In vitro studies VEGF stimulates the growth of mesothelioma 
cells and anti-VEGF rabbit polyclonal antibodies inhibit their growth [37-39].  
 
The co-expression of c-kit in 26% [40] of mesothelioma has inspired the use of imatinib, 
an inhibitor of bcr/abl, c-kit and PDGFR and . Four phase II clinical trials of imatinib as 
a single agent in mesothelioma have been published. Of a total of 94 patients treated, 
no objective response was seen and progression free survival was less than two months 
[41, 42], [43, 44] . 
 
Sorafenib is a potent inhibitor of VEGFR2, VEGFR3, Raf, PDGFR and c-kit. In a phase 
II trial with 50 patients evaluable for response three partial responses and 27 disease 
stabilizations were observed, results deemed insufficient for further evaluation of 
sorafenib [45]. Another phase II trial assessed sorafenib in a single-arm phase II study 
enrolling 53 patients using a Simon's two-stage design. Treatment was well tolerated 
and demonstrated a moderate activity with a median PFS of 5·1 months [46] . 
 
 at U
niversitaet Zuerich on Septem
ber 15, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
8 
 
Sunitinib, a VEGFR1, VEGFR2, VEGFR3, PDGFR, and c-kit TKI was tested in a phase 
II trial in 53 patients resulting in partial responses in 6 and stable disease in 34. An 
accompanying biomarker study was unsuccessful [47]. Another phase II trial using a 
Simon’s two-stage design and a primary outcome of objective response rate did not 
meet the criteria for continuing to the second stage of accrual, with only one partial 
response observed among 35 patients [48] . A phase I trial with an expansion cohort in 
mesothelioma patients demonstrated that sunitinib was not well tolerated at 37·5 mg 
with standard pemetrexed and cisplatin doses, requiring dose reductions mainly due to 
cumulative myelosuppression and subsequent limited activity [49] . 
 
Pazopanib, a broad anti-angiogenic broad TKI targeting VEGFR1-3, PDGFR and , 
and c-kit, has been evaluated in a phase II trial as a single agent single agent in 34 
mesothelioma patients resulting in a six months progression-free survival of 48% (Table 
1). Vatalanib targets VEGFR1, VEGFR2, c-kit, PDGFR and c-Fms. It was tested in a 
phase II trial and did not achieve the protocol-specified three-months PFS, ending its 
development mesothelioma [50]. Cediranib is a VEGFR 1-3 TKI. Two phase II trials 
were able to show only a modest single-agent activity with partial remission in four and 
five patients out of in 54 and 51 patients respectively, however with significant toxicities 
[51, 52] . 
 
Dasatinib is an inhibitor of the Src family of non-receptor tyrosine kinases and PDGFR. 
Single-agent dasatinib did not show any activity in mesothelioma and was associated 
with inacceptable pulmonary toxicities in a phase II trial enrolling 46 patients [53] . 
 
While the results from most of these trials were considered as negative, the fact remains 
that activity of cediranib, imatinib, sunitinib or sorafenib was observed in a low proportion 
of patients, suggesting a need for the identification of predictive biomarkers to support 
further development. However, given the multitargeted nature of these TKIs and the 
difficulties encountered in identifying biomarkers for anti-angiogenic therapies in general 
this will unlikely be successful. 
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Due to the few responses to TKIs, combinatorial regimens with chemotherapy are 
ongoing. To this end, a study with cediranib in combination with chemotherapy is 
currently recruiting (Table 1) and another trial phase I/II trial has been randomizing 
patients to cisplatin and pemetrexed with or without axitinib, a pan-VEGFR inhibitor 
(Table 1). Several trials combining chemotherapy with multitargeted TKIs are still being 
discussed or currently in phase I (Table 1).  
 
Restricted TKI 
Erlotinib and gefitinib are first generation TKIs targeting specifically EGFR. EGFR 
expression has been demonstrated by immunohistochemistry in 70% - 95% of 
mesothelioma specimens and its overexpression might be associated with a favourable 
prognosis [54-56]. Despite some encouraging in vitro data, phase II trials in patients with 
untreated mesothelioma using gefitinib or erlotinib have failed to demonstrate significant 
activity. Gefitinib demonstrated partial remissions in two out of 43 untreated patients 
[56]. Erlotinib was ineffective in 63 untreated patients despite high expression of EGFR 
in patients’ tumors. Here, the activation of the PI3K/Akt downstream pathways was 
proposed as a potential mechanism of primary resistance [57]. Also the combination of 
erlotinib and bevacizumab after platinum-based chemotherapy did not result in any 
responses among 24 mesothelioma patients [58] .  
Other targets including MET- and FGFR3-TKIs, tiventanib and dovitinib, are under 
investigation (Table 1). 
 
Histone deacetylase inhibitors 
 
The equilibrium between the acetylated or deacetylated forms of histone proteins is 
regulated by histone acetyltransferase and histone deacetylase (HDAC). HDAC 
inhibitors will alter the wrapping DNA around histones, modify the access of transcription 
factors and consequently impact the expression of various genes.  
 
After two promising phase I trials including small numbers of mesothelioma treated by 
vorinostat as monotherapy or combined with chemotherapy, [59] a placebo-controlled 
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phase III trial including 660 mesothelioma patients who had progressed after treatment 
with pemetrexed and platinum was launched. Results were reported at ECCO-ESMO 
2011 and were negative for all endpoints [60] .  Another small phase II trial with the 
HDAC inhibitor belinostat was also negative [61]. 
 
In vitro data suggested valproic acid might have a proapoptotic effect in synergy with 
doxorubicine. A phase II trial evaluating valproic acid in combination with doxorubicine in 
45 patients pre-treated with chemotherapy demonstrated objective responses in seven 
with a median progression-free survival of 2·5 months [62].  
 
 
Proteasome Inhibitors 
 
Bortezomib was found to be inactive in a single-arm phase II trial in poor performance-
status first-line and second-line mesothelioma patients with only one confirmed 
response of 33 patients [63]. Bortezomib was also evaluated in combination with 
cisplatin in a prospective phase II trial with progression-free survival rate at 18 weeks as 
primary end-point [64]. 82 patients were treated with an 18 weeks progression-free 
survival of 53%. Based on statistical assumptions, the null hypothesis could not be 
rejected and the combination was considered not worthy of further investigation. 
 
Bevacizumab 
 
A randomized phase II trial of untreated mesothelioma patients compared cisplatin-
gemcitabine alone or with bevacizumab.  The addition of bevacizumab did not improve 
response, progression-free survival, or overall survival compared to chemotherapy 
alone. A potential benefit in patients with low circulating levels of VEGF was suggested 
in subgroup analysis [65]. Another phase II trial combined treatment of cisplatin and 
pemetrexed with bevacizumab in 45 inoperable chemotherapy naïve mesothelioma 
patients. Response rate of 41%, median PFS of 6·9 months, and median OS 15·3 
months were reported, with development of hypertension as a possible surrogate 
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marker for bevacizumab activity  [66]. 
 
A two-armed phase II/III trial compared the standard of care cisplatin and pemetrexed 
regimen with or without bevacizumab as first-line treatment and maintenance in 
inoperable mesothelioma patients. While tolerance was good, the preliminary analysis of 
the study revealed that disease control at six months favoured the bevacizumab arm 
(73·5% and 43·2%, P = 0·010). Final results of this trial are eagerly awaited [67]. 
 
Other anti-angiogenic interventions 
 
Vascular Disrupting Agents  
BNC105P is a small molecule inhibiting tubulin polymerisation that functions as a 
vascular disrupting agent through selectively shutting down tumor blood vessels without 
affecting normal vasculature. Preclinical models have demonstrated significant tumor 
growth suppression and regression with BNC105P [68] .VDA BNC105P was tested as a 
second line treatment in advanced mesothelioma and proven ineffective in a trial of 30 
patients [69]. 
 
Thalidomide  
Thalidomide is the oldest and perhaps the most extensively studied drug classified as an 
anti-angiogenic agent, which activity is attributed to the inhibition of VEGF, basic 
fibroblast growth factor, as well as TGF and TNF[70, 71] A phase I trial explored its 
activity in 40 mesothelioma patients, a third of them being treatment naive. There were 
no responders, with an OS of 7·6 months and eleven were free of progression after six 
months [72]. Two parallel unpublished phase II studies evaluated thalidomide in 
combination with gemcitabine/cisplatin or thalidomide as a single agent. Thirty-one 
chemotherapy naïve patients received thalidomide and gemcitabine/cisplatin with partial 
responses in 14% and an OS of 11 months [73]. Twenty-seven patients pre-treated or 
unsuitable for chemotherapy were treated with single agent thalidomide. Responses 
occurred in 6% of the patients, and OS was 11 months. 
 
 at U
niversitaet Zuerich on Septem
ber 15, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
12 
 
The utility of thalidomide in mesothelioma as maintenance therapy for up to one year 
was evaluated in a large randomized phase III trial in 222 patients who had not 
progressed after four to six cycles of pemetrexed with or without platinum. The primary 
endpoint of of time to progression was of 3.6 months in the experimental arm as 
compared to 3·5 months in the placebo arm, demonstrating the absence of benefit of 
thalidomide maintenance [74]. 
 
NGR-hTNF  
NGR-hTNF consists of human tumor necrosis factor alpha (hTNF-alpha) fused to the 
tumor-homing peptide asparagine-glycine-arginine (NGR) able to selectively bind an 
aminopeptidase N isoform overexpressed on tumor blood vessels. Based on an 
exploratory phase II trial in mesothelioma a phase III trial comparing NGR-hTNF to best 
supportive care is ongoing [75] . 
 
Immunotherapeutic approaches 
 
In mesothelioma, a chronic inflammatory response represented by infiltrating 
lymphocytes and plasma cells was associated with a better prognosis [76]. As in other 
tumors, immunotherapeutic strategies aimed at balancing the immune system in favour 
of an anti-mesothelioma response are being explored (Figure 2).    
 
Transforming growth factor β  
Transforming growth factor β (TGF-) is a pleiotropic cytokine which can be produced by 
cancer, stroma and immune cells [77-79] .TGF- attenuates the anti-tumor immune 
response blocking priming and effector phase of tumor-specific T cells.  Fresolimumab 
(GC1008), a humanized monoclonal antibody neutralizing active forms of TGF-β, has 
been examined in a phase I trial in 13 patients with mesothelioma [80]. No objective 
response was seen, but three patients had stable disease at three months and five 
patients developed an enhanced antibody response to mesothelioma lysates (Table 2). 
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Interferon-interferon
Interferon-(IFN-) is type 1 cytokine with multiple functions resulting in antiviral, anti-
proliferative, anti-angiogenic activity and immune cell stimulation. IFN- has been 
delivered by an adenoviral vector into the pleural effusion of patient with mesothelioma 
in two phase I trials, using one or two injections [81, 82]. Both trials found a transient 
increase of IFN- in the pleural cavity, mitigated by a neutralizing antibody response 
resulting in clearance of the adenovirus and decrease of IFN-. There were no safety 
issues and antibody responses against the mesothelin could be induced in some 
patients. Of the 13 patients treated four had stable disease as best response. 
IFN- can promote the differentiation and activity of host immune cells and moreover 
correlates with generation of a durable antitumor response [83]; one clinical study 
exploring the efficacy of this cytokine in mesothelioma showed a response in about 30% 
of patients when associated with chemotherapy, however with major toxicity [84]. One 
phase I trial have shown potential therapeutic benefit of IFN- 2a gene transfer 
mediated by an adenoviral vector [85] and a new study with this approach is still ongoing 
(see Table 2).  
 
Intrapleural viruses 
Viruses are strong stimulants to the immune system by the activation of the innate as 
well as the adaptive responses. The measles virus is oncolytic, resulting in tumor cell 
death and antigen release, allowing T cell priming through dendritic cells. Also, 
immunoadjuvant properties of the measles virus were shown by loading dendritic cells 
with measles-infected mesothelioma cells, which resulted in dendritic cell maturation 
[86]. Phase I clinical trials are under way testing the intrapleural application of measles, 
herpes and vaccinia virus in patients with malignant pleural mesothelioma (Table 2). 
 
Immune checkpoint inhibition 
Cancer cells often inhibit T-cell activation in order to escape immune surveillance. After 
activation T cells express the cytotoxic T-lymphocyte antigen 4 (CTLA-4). When CTLA-4 
binds members of the B7 family the T-cell response becomes abrogated [87.] Blocking 
monoclonal antibodies have been developed to prevent the negative feedback loop via 
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CTLA-4. Tremelimumab, is a humanized monoclonal IgG2 antibody binding to CTLA-4. 
Tremelimumab has been tested as second line in mesothelioma in a phase II trial [88]. 
Two of 29 patents had durable partial responses. Although the primary endpoint of the 
study was not met, the disease control rate of 31% and progression-free survival of six 
months prompted further evaluation in an ongoing randomized phase II study (Table 2).  
Expression of PD-L1 allows cancers to evade the host immune system by interaction 
with PD1. Treatment with antibodies targeting these molecules has resulted in 
extraordinary responses for advanced melanoma and lung cancer. Recently, the 
expression of PD-L1 it has been demonstrated in mesothelioma [89]. Therefore, 
therapies targeting this pathway are of major interest and under development for 
mesothelioma patients. 
 
 
Mesothelin  
Mesothelin is a cell surface glycoprotein expressed in mesothelial and peritoneal cells. 
Even if the biological function of mesothelin it not fully understood, it is known that 
mesothelin binds to CA-125 and is involved in cell adhesion (reviewed in [90]). 
Amatuximab is a chimeric IgG1 antibody targeting mesothelin. Studies demonstrated 
that it blocks the binding of mesothelin to CA-125 and thus could be used also as a 
strategy to prevent tumor metastasis [91]. Amatuximab was well tolerated in a phase I 
trial [92] and currently is tested in phase II in patients with mesothelioma (Table 2). 
Antibodies can be used to deliver cytotoxic agents to antigen expressing malignant cells. 
The potent bacterial toxin Pseudomonas exotoxin A (PE38) was linked to a disulfide 
stabilized variable fragment based on the affinity modified variable light and heavy chain 
of amatuximab (SS1(dsFv)PE38) and showed pre-clinical activity [93]. SS1(dsFv)PE38 
is under clinical investigation and was shown to be safe in two phase I trials, in which 16 
patients with mesothelioma were treated. Only minor antitumor activity could be 
observed. Additionally, the development of neutralizing antibodies was observed in 24% 
of patients prevented its use for more than one cycle [94].  In a subsequent pilot study 
using immunosuppressive pre-treatment with pentostatin and cyclophosphamide to 
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prevent neutralizing antibodies and allow delivery of more courses of treatment, three of 
ten evaluable patients had major responses [95].  
MF-T is a fully humanized anti-mesothelin antibody conjugated to microtubule-targeting 
toxophore DM4 (BAY 94-9343). It showed selective cytotoxicity against mesothelioma 
cells, while sparing normal mesothelial cells, and potent in vivo activity against cell line 
and tumor xenografts [96]. This compound is thus a likely relevant candidate for further 
clinical testing. 
In contrast to these described passive immunological interventions mesothelin can be 
targeted by active specific vaccination. Live-attenuated Listeria vaccine expressing 
mesothelin has been tested in a phase I study with mesothelin-expressing tumors. CRS-
207 was well tolerated and mesothelin-specific CD8 T cell responses were detected 
[97]. Recent data presented at ASCO 2014, showed that CRS-207 can be safely 
combined with standard of care chemotherapy and showed encouraging anti-tumor 
activity with 9 out of 15 subjects having confirmed durable PR and 4 SD (Table 2). 
 
Wilms tumor suppressor gene 1  
The Wilms tumor suppressor gene 1 (WT1), is a transcription factor highly expressed in 
mesothelioma and WT1 immunohistochemistry is among the routine procedures used 
for the diagnosis of mesothelioma. WT1 peptides are immunogenic and induce T cell 
responses against mesothelioma cell lines [98]. In a first clinical trial class I and II WT1 
peptides were used for vaccination with subcutaneous GM-CSF, which is used to 
mature dendritic cells to augment T cell priming. Out of nine patients with mesothelioma 
treated, one remained without progression after three years and five were documented 
to have a CD8 T-cell response [99]. Currently, randomized phase II trials with this 
vaccine are ongoing in patients after completion of multimodality therapy (Table 2). 
 
Vaccination with tumor cell lysate 
Mesothelioma cell lysates are used for vaccination and can induce an antitumoral  
response. Twenty-two patients were treated with autologous tumor cell lysates and GM-
CSF. In 32% of the patient an immune response could be induced, but there was no 
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objective response [100]. One clinical phase I trial is testing an autologous tumor cell 
vaccine with an adjuvant (ISCOMATRIX) and celecoxib to augment antigen 
presentation. The tumor cell vaccine is exposed ex vivo to demethylating agents to 
increase expression of tumor antigens (Table 2). Another phase one trial evaluates an 
allogeneic tumor cell vaccine (K526-GM) in combination with cyclophosphamide and 
celecoxib (Table 2). Cyclophosphamide is intended to eradicate regulatory T cells, which 
can inhibit dendritic cells to prime effector T cells [101] . Celecoxib is a COX-2 inhibitor 
resulting in decreased prostaglandin E2 (PGE2) and was used to block PGE2-mediated 
conversion of regulatory T cells and to allow dendritic cell maturation [102]. 
 
Cellular therapy 
Adoptive transfer of dendritic cells pulsed ex vivo with tumor-antigens led to the first 
FDA approved cellular therapy (Sipuleucel-T) in prostate cancer [103]. In mesothelioma 
a comparable approach was tested in 10 patients vaccinated with autologous dendritic 
cells. Each vaccine was composed of mature dendritic cells pulsed with autologous 
tumor lysate [104]. In four patients, dendritic cell vaccination induced cytotoxic T cells. 
Results from a trial evaluating dendritic cell-based vaccination in combination with low-
dose cyclophosphamide are awaited (Table 2).  
 
T cells can be re-directed against specific antigens. After gene transfer, autologous T 
cells express a chimeric antigen receptor (CAR), which enables the T cell to destroy 
target cells. Mesothelin-specific re-directed T cells were developed and showed in vitro 
and in vivo activity [105, 106]. To achieve transient expression the plasmid with the gene 
sequence of the CAR was transferred in the T cells by electroporation [107]. Mesothelin-
specific re-directed T cells are tested in early clinical trials (Table 2). An alternative 
target in malignant mesothelioma is the fibroblast activation protein (FAP) [108, 109]. 
FAP-specific re-directed T cells demonstrated antigen-specific activity in vitro and in vivo 
and are close to early clinical investigation (Table 2) [108, 110] . In this clinical trial the 
adoptive transfer is planned to be performed into the pleural effusion to overcome 
blocked T-cells trafficking [111]. 
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Discussion 
In contrast to lung cancer, oncogenic driver mutations are absent in malignant 
mesothelioma. The development of targeted therapy therefore hinges on the exploration 
of pathways indirectly activated by the loss of tumor suppressor genes or targets 
associated with the disease phenotype. Efforts of targeting angiogenesis and cancer 
associated receptor tyrosine kinases have shown disappointing results despite the 
enrolment of hundreds of mesothelioma patients in clinical trials. Histone deacetylase 
and proteasome inhibitors were found to be inactive. The promising avenues for 
targeted therapies in mesothelioma include the functional consequences of alterations in 
NF2/Hippo pathway, and immunotherapeutic approaches. The inactivation of NF-2 and 
resulting merlin deficiency leads to a significantly increased activity of several pathways, 
including the hedgehog pathway, the activity of the focal adhesion kinase (FAK) and the 
PI3K/mTOR pathway. Inhibition of these pathways resulted in reproducible growth 
reduction of mesothelioma in preclinical models. Phase I trials in mesothelioma 
demonstrated clinical activity of FAK and of PI3K/mTOR inhibitors and a randomized 
phase II trial of the FAK inhibitor defactinib as maintenance therapy after chemotherapy 
has been initiated. In regard to immunotherapeutic approaches the jury is still out. 
However, based on early results in non-small cell lung cancer and other solid tumors it 
appears likely that immune checkpoint inhibitors will find a place in the therapy of 
mesothelioma.  
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Figure legends 
Figure 1. Genetic/epigenetic changes present in mesothelioma offer different 
possibilities for therapeutic intervention. Functional inactivation of NF2 and 
NF2/Hippo pathway offers the opportunity to intervene using focal adhesion kinase 
(FAK) inhibitors, PI3/mTOR dual inhibitors, microtubule stabilizing agents, E3 ubiquitin 
ligase CRL4/DCAF inhibitors, tumor suppressor miR delivery, inhibitors of the interaction 
between YAP and TEAD transcription activators, and 7 transmembrane G-coupled 
receptors (7TMGCPR) inhibitors regulating YAP activity. Tumor promoting activity of 
high mobility group-box-1 (HMGB1) can be blocked using HMGB1 antibodies. 
Auxotrophy for arginine render the tumor sensitive to the activity of arginine deiminase. 
Calretinin-dependent survival can be blocked by calretinin silencing. 
Figure 2. Interplay of the immune system with malignant mesothelioma and 
possible immunotherapeutic interventions. Malignant mesothelioma cells express 
tumor antigens like WT1, FAP, mesothelin. Tumor-antigens or other components from 
the malignant cells can be picked up by dendritic cells and presented to T cells inducing 
a T-cell response. However, molecules like TGF- can block T cell priming in the lymph 
node or T cell function in malignant tissue. T cell function can be also abrogated by 
activation of CTLA-4 and PD-1 on primed T cells. In addition, effector T cells can be 
converted in immunosuppressive regulatory T cells. Dendritic cell and re-directed T cells 
can be adoptively transferred. Dendritic cells loaded with peptides derived from tumor-
antigen induce T cells response. To enhance priming GM-CSF is given in combination 
with dendritic cells. To circumvent T-cells priming re-directed effector T cells can be 
transferred. IFN- is used to augment MHC expression on tumor cells increasing 
immunogenicity. 
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Table 1 Clinical trials investigating targeted therapy in mesothelioma 
    
        
target clinical trial ID experimental arm mechanism control arm phase primary endpoints 
expected 
completion date 
chemotherapy sensitizer NCT00700336 CBP501 plus Cis/Pem G2 checkpoint inhibition Cis/Pem I/II safety, MTD, PFS  completed 
altered NF2 signaling NCT01138033 GSK2256098 Focal Adhesion Kinase inhibitor   I MTD December 2014 
  NCT01870609 VS-6063 Focal Adhesion Kinase inhibitor Placebo II OS, PFS December 2016 
  NCT02004028 VS-6064 Focal Adhesion Kinase inhibitor   II PK November 2014 
altered NF2 signaling NCT00854152 GDC-0980 PI3K/mTOR inhibitor   I PK, MTD August 2014 
  NCT01655225 LY3023414 PI3K/mTOR inhibitor   I 
Recommended Phase 2 
dose September 2014 
altered NF2 signaling NCT00770120 Everolimus mTOR inhibitor   II PFS, RR completed 
  NCT01024946 Everolimus mTOR inhibitor   II PFS, RR completed 
arginine dependency NCT01279967 Pegylated Arginine Deiminase Growth inhibition of ASS negative tumors Best supportive care II PFS January 2014 
receptor tyrosine kinases NCT00402766 Imatinib mesylate plus Cis/Pem bcr/abl, c-kit and PDGFR TKI   I MTD August 2015 
  NCT00703638 Sorafenib plus Cis/Pem VEGFR2, VEGFR3, Raf, PDGFR, and c-kit TKI   I MTD Completed 
  NCT01064648 Cediranib plus Cis/Pem VEGFR 1-3  Placebo (phase II) I/II MTD June 2014 
  NCT00700336 Dasatinib Src inhibition and PDGFR TKI   I 
modulation of p-Src 
Tyr419 March 2016 
  NCT01592383 Erlotinib EGFR TKI   II RR June 2015 
  NCT00459862 Pazopanib VEGFR1-3, PDGFR  and c-Kit   II PFS completed 
  NCT01211275 Axitinib pan-VEGFR inhibitor  Cis/pem I/II safety/efficacy unknown 
  NCT01861301 Tivantinib   MET inhibitor   II ORR February 2015 
  NCT02049060 Tivantinib plus Carbo/Pem MET inhibitor   I DLTs July 2014 
  NCT01590160 Ganetespib plus Cis/Pem Hsp90 inhibitor     I/II DLTs December 2015 
  NCT01307100 Nintedanib plus Cis/Pem VEGFR, PDGFR and FGFR TKI Cis/Pem II PFS May 2016 
  NCT01769547 Dovitinib FGFR3 inhibitor   II PFS June 2016 
proteasome NCT00996385 Bortezomib and oxaliplatin proteasome inhibitor    II RR  September 2013 
aminopeptidase N NCT01358084 NGR-hTNF  TNF targeting tumor blood vessels Best supportive care II PFS June 2013 
 
 at U
niversitaet Zuerich on Septem
ber 15, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Table 2 Clinical trials investigating immunotherapy in mesothelioma 
    
        
Target clinical trial ID experimental arm mechanism control arm phase 
primary 
endpoints expected completion date 
immunosuppressive cytokine NCT01112293 anti-TGF- monoclonal 
antibody (GC1008) 
Blocking TGF-   II PFS October 2012 
immunomodulating cytokine NCT01212367 Gene transfer IFN-alfa 
2a 
immunomodulating 
cytokine 
  
I safety December 2027 
immunoadjuvant NCT01503177 intrapleural measles 
virus  
Dendritic cell maturation; 
oncolytic virus 
  I safety September 2014 
  NCT01721018 intrapleural herpes virus  Oncolytic virus   I/II safety, PFS April 2014 
  NCT01766739 intrapleural vaccinia 
virus (GL-ONC1) 
Oncolytic virus   I safety January 2015 
immune checkpoint NCT01843374  Tremelimumab Blocking CTLA-4 Placebo II OS May 2016 
tumor-antigen passive NCT00738582 MORAb-009 
(Amatuximab) 
anti-Mesothelin 
monoclonal antibody with 
With pemetrexed and 
cisplatin 
  II PFS November 2014 
tumor-antigen active-specific NCT01675765 CRS-207 live-attenuated 
Listeria vaccine 
expressing mesothelin 
active-specific immune 
response against 
mesothelin followed 
pemetrexed and cisplatin 
  I safety December 2015 
  NCT01265433 WT-1 analog peptide 
Vaccine plus GM-CSF 
adjuvant, active-specific 
immune response against 
WT-1 
Montanide 
adjuvant + GM-
CSF 
II PFS December 2014 
  NCT01890980 WT-1 analog peptide 
Vaccine plus GM-CSF 
adjuvant, active-specific 
immune response against 
WT-1 
Montanide 
adjuvant + GM-
CSF 
II PFS December 2017 
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  NCT01258868 Autologous tumor cell 
vaccine 
active-specific immune 
response against 
autologous tumor cells in 
combination with 
celecoxib and 
ISCOMATRIX 
  I safety November 2018 
  NCT01143545 Allogeneic tumor cell 
vaccine 
active-specific immune 
response against 
allogeneic tumor cells in 
combination with 
cyclophosphamide and 
celecoxib 
  I safety May 2017 
  NCT01569919 TroVax: pox virus 
specific for antigen 5T4  
Pox virus carrying the 
5T4 antigen plus Cis/Pem 
  II Immune 
responses 
to 5T4, 
safety 
June 2014 
  NCT00280982 tumor lysate-loaded 
autologous dendritic 
cells 
active-specific immune 
response against 
autologous tumor cells 
  I safety completed 
tumor-antigen active-specific 
adoptive transfer 
NCT01241682 tumor lysate-loaded 
autologous dendritic 
cells low-dose 
cyclophosphamide 
active-specific immune 
response against 
autologous tumor cells 
  I safety completed 
tumor-antigen adoptive transfer NCT01583686 Adoptive transfer of 
mesothelin-specific re-
directed T cells 
T cell response   I/II safety/PFS March 2019 
  NCT01355965 Adoptive transfer of 
mesothelin-specific re-
directed T cells 
T cell response   I safety May 2014 
  NCT01722149  Adoptive transfer of 
FAP-specific re-directed 
T cells 
T cell response   I safety May 2015 
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